Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Systematic immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival.

ABSTRACT: Systematic immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival.

PROVIDER: PRJNA470891 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7145320.fastq.gz	Fastqsanger.gz
	SRR7145330.fastq.gz	Fastqsanger.gz
	SRR7145340.fastq.gz	Fastqsanger.gz
	SRR7145350.fastq.gz	Fastqsanger.gz
	SRR7145360.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 62

Similar Datasets

Systematic immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival.

Project description:Success of immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC) has invigorated their use in neo-adjuvant setting for early-stage disease. However, the cellular and molecular mechanisms of the early immune responses to therapy remain poorly understood. Through an integrated analysis of early-stage NSCLC patients and a Kras-mutant mouse model, we show a prevalent programmed cell death 1/ programmed cell death 1 ligand 1 (PD-1/PD-L1) axis exemplified by increased intratumoral PD-1+ T cells and PD-L1 expression. Notably, tumor progression was associated with spatiotemporal modulation of the immune microenvironment. Importantly, PD-1 inhibition controlled tumor growth, improved overall survival, and reprogrammed tumor-associated lymphoid and myeloid cells. Depletion of T lymphocyte subsets demonstrated synergistic effects of those populations on PD-1 inhibition of tumor growth. Transcriptome analyses revealed T cell subset-specific alterations corresponding to degree of response to the treatment. These results provide insights into temporal evolution of the phenotypic effects of PD-1/PD-L1 activation and inhibition, and motivate targeting this axis early in lung cancer progression.

2018-07-26 | GSE114300 | GEO

Project description:Systematic immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival.

| PRJNA470948 | ENA

Optogenetic mitochondrial preconditioning enhances cardiomyocyte survival under stress

Project description:Optogenetic mitochondrial preconditioning enhances cardiomyocyte survival under stress

| PRJNA1226613 | ENA

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

Project description:Glioblastoma is the most common primary malignant brain tumor in adults and associated with poor survival. Standard-of-care chemotherapy and radiation confer a median overall survival of under two years. The Ivy Foundation Early Phase Clinical Trials Consortium conducted a randomized, multi institution clinical trial to evaluate immune responses and survival following neoadjuvant and/or adjuvant therapy with pembrolizumab, a programmed cell death protein 1 (PD-1) monoclonal antibody, in 35 patients with recurrent, surgically resectable glioblastoma. Patients who were randomized to receive neoadjuvant pembrolizumab, with continued adjuvant therapy following surgery, had significantly extended overall survival compared to patients that were randomized to receive adjuvant, post-surgical PD-1 blockade alone (hazard ratio = 0.39; P = 0.04, log-rank test). Neoadjuvant PD-1 blockade was associated with upregulation of T cell and interferon-γ-related genes, but downregulation of cell cycle related genes within the tumor, which was not seen in patients that received adjuvant therapy alone. Focal induction of programmed death-ligand 1 (PD-L1) in the tumor microenvironment was observed more frequently in the neoadjuvant group than in tumors obtained from patients treated only in the adjuvant setting. Similarly, neoadjuvant pembrolizumab was associated with clonal T cell expansion and the overlap of T cell receptors between tumor and blood, decreased PD-1 expression in T cells and a decreasing peripheral monocytic population. These findings suggest that the neoadjuvant administration of PD-1 blockade enhances the local and systemic anti-tumor immune response and may represent a more efficacious approach to the treatment of this uniformly lethal brain tumor. This trial was registered with ClinicalTrials.gov under the identifier NCT02852655 (https://clinicaltrials.gov/ct2/show/NCT02852655).

2018-12-05 | GSE121810 | GEO

Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival.

Project description:Success of immune checkpoint inhibitors in advanced non-small-cell lung cancer (NSCLC) has invigorated their use in the neoadjuvant setting for early-stage disease. However, the cellular and molecular mechanisms of the early immune responses to therapy remain poorly understood. Through an integrated analysis of early-stage NSCLC patients and a Kras mutant mouse model, we show a prevalent programmed cell death 1/programmed cell death 1 ligand 1 (PD-1/PD-L1) axis exemplified by increased intratumoral PD-1+ T cells and PD-L1 expression. Notably, tumor progression was associated with spatiotemporal modulation of the immune microenvironment with dominant immunosuppressive phenotypes at later phases of tumor growth. Importantly, PD-1 inhibition controlled tumor growth, improved overall survival, and reprogrammed tumor-associated lymphoid and myeloid cells. Depletion of T lymphocyte subsets demonstrated synergistic effects of those populations on PD-1 inhibition of tumor growth. Transcriptome analyses revealed T cell subset-specific alterations corresponding to degree of response to the treatment. These results provide insights into temporal evolution of the phenotypic effects of PD-1/PD-L1 activation and inhibition and motivate targeting of this axis early in lung cancer progression.

| S-EPMC6101707 | biostudies-literature

A Gene Expression Signature Predicts Survival of Patients with Stage I Non-Small Cell Lung Cancer

Project description:We applied a meta-analysis of datasets from seven different microarray studies on lung cancer for differentially expressed genes related to survival time (under 2 y and over 5 y). Systematic bias adjustment in the datasets was performed by distance-weighted discrimination (DWD). We identified a gene expression signature consisting of 64 genes that is highly predictive of which stage I lung cancer patients may benefit from more aggressive therapy. Keywords: disease state analysis

2006-11-10 | GSE6253 | GEO

Inhibition of MAN2A1 enhances tumor response to anti-PD-L1

Project description:Inhibition of MAN2A1 enhances tumor response to anti-PD-L1

| PRJNA640958 | ENA

Hexokinase 3 enhances myeloid cell survival via non-glycolytic functions

Project description:Hexokinase 3 enhances myeloid cell survival via non-glycolytic functions

| PRJNA809305 | ENA

Inosine enhances mitochondria respiration to promote cancer survival under starvation

Project description:Inosine enhances mitochondria respiration to promote cancer survival under starvation

| PRJNA936873 | ENA

An adult-stage transcriptional program for survival of serotonergic connectivity

Project description:An adult-stage transcriptional program for survival of serotonergic connectivity